On Monday, ResMed earned an upgrade to its Relative Strength (RS) Rating, from 79 to 83.
Risk Management In The Stock Market: How Much Money To Invest Now
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.
ResMed is building a cup without handle with a 263.05 buy point. See if it can break out in heavy volume.
ResMed showed 11% earnings growth in the latest quarterly report, while sales growth came in at 8%.
ResMed holds the No. 5 rank among its peers in the Medical-Products industry group. Boston Scientific is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
